MindMaze Therapeutics Narrows Losses and Prepares for Commercial Takeoff in 2026

MindMaze Therapeutics’ 2025 Annual Report tells a story of transition—one where financial discipline begins to align with long-term commercial ambition. The Swiss-based neurotechnology company gears up for a broader market launch in 2026.

Mindmaze reported CHF 0.6 million in revenue for 2025, alongside operating expenses of CHF 11.2 million and a net loss of CHF 9.9 million. At first glance, the deficit reflects a business still in build-out mode. But more importantly, it highlights a company that is actively channeling resources into scaling its platform, rather than one struggling to find direction.

This level of loss is not unusual for a health technology firm at this stage—particularly one that has just completed a major business combination and is investing heavily in infrastructure, clinical validation, and market access. In MindMaze’s case, 2025 marked the integration of NeuroX and Relief Therapeutics, forming a more focused, commercial-stage entity centered on precision neurotherapeutics.

What stands out is not just the loss itself, but how it is being deployed. Investments have been directed toward expanding the company’s neurotherapeutics platform, building its U.S. commercial presence, and advancing reimbursement pathways—especially for home-based therapy. These are foundational steps for a company aiming to operate at scale in a highly regulated healthcare environment.

At the same time, MindMaze is strengthening its case for adoption through real-world evidence. Results from a multi-site program with Vibra Healthcare demonstrated meaningful improvements in patient outcomes and therapy intensity, reinforcing both the clinical and economic value of its solution. This kind of validation is essential for unlocking reimbursement and accelerating revenue growth in the years ahead.

Leadership changes also signal a shift toward execution. The appointment of CEO Zach Henderson, a seasoned operator in health technology, reflects a clear priority: turning a validated platform into a commercially viable business. His mandate is straightforward—expand access, scale adoption, and deliver measurable outcomes.

Looking ahead, 2026 is shaping up to be a pivotal year. The company plans to expand its U.S. footprint, establish a headquarters and patient experience lab, and grow its commercial teams across sales, marketing, and customer success. At the same time, it will continue to pursue strategic partnerships and broaden payer coverage to support its reimbursable care model.

➡️ Source: Mindmaze Press Release |  📸 ©Mindmaze